Zavabresib (OPN-2853, selective BET inhibitor)
Current understanding
To be populated as evidence accumulates.
Evidence log
- January 21 — Zavabresib Earns FDA Orphan Drug Designation in Myelofibrosis: 2026 — FDA granted Orphan Drug Designation for myelofibrosis; combination with ruxolitinib reported durable spleen reduction in patients with inadequate ruxolitinib response (regulatory milestone + early clinical signal, non-trial press/announcement evidence). (novelty: 3)
Open questions
Related
Contributing findings
Zavabresib Earns FDA Orphan Drug Designation in Myelofibrosis
January 21, 2026
novelty 3
per-area 4
introduces